Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics. However, immune-related adverse events (irAEs) increase morbidity and mortality and thereby limit therapeutic utility. The real-world incidence of the entire spectrum of pulmonary irAEs has not been systematically described. The objective of this study is to assess the risk of developing pulmonary irAEs (pneumonitis, pleural events [i.e., effusion and pleurisy], exacerbations of airway disease [i.e., bronchitis and bronchiectasis], and sarcoidosis) with exposure to five commonly used ICIs: nivolumab, pembrolizumab, durvalumab, avelumab, and atezolizumab.

Methods

We conducted a retrospective review of the Food and Drug Administration Adverse Events Reporting System (FAERS) pharmacovigila

SUBMITTER: Ebinama U 

PROVIDER: S-EPMC10734392 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature